Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Vasovist · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Arm 1 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Vasovist (BAY86-5283, MS-325) | DRUG | All patients receive a single IV bolus injection of Vasovist at a dose of 0,03 mmol/kg BW at a flowrate of 0,5 mL/sec, followed by a saline flush of at least 30 mL |
Inclusion Criteria: * Patients with a certain circulation disorder (aortoiliac disease Fontaine-stage IIb / IV) and an indication for the evaluation of the peripheral run-off arteries from the infrarenal aorta to the calves * Patients who are scheduled for X-ray angiography and magnetic resonance a...
Vasovist is an investigational small molecule being developed for peripheral vascular diseases. It is a contrast agent studied for use in magnetic resonance angiography (MRA) to image peripheral artery disease. It is currently in Phase 3 clinical development and is not yet approved.
Vasovist is being developed by Bayer AG, a company traded under the ticker BAYRY. The drug is currently in Phase 3 clinical trials for peripheral vascular diseases, specifically for use in magnetic resonance angiography.
Vasovist is in Phase 3 clinical development. It has completed one Phase 3 trial, which was an uncontrolled study of 261 patients with peripheral artery disease. The drug is investigational and has not been approved.
Vasovist has one completed Phase 3 clinical trial, identified as NCT00296855. This study compared Vasovist magnetic resonance angiography (MRA) with an MRA using a conventional extracellular contrast agent, alongside X-ray angiography, in patients with peripheral artery disease.
Vasovist is a small molecule contrast agent used in magnetic resonance angiography (MRA). It is designed to enhance imaging of blood vessels in patients with peripheral artery disease, helping to visualize vascular structures during diagnostic procedures.